Workflow
QIANHAI HEALTH(00911)
icon
Search documents
前海健康(00911) - 截至2025年7月31日止之股份发行人的证券变动月报表
2025-08-01 04:08
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 FF301 FF301 II. 已發行股份及/或庫存股份變動 致:香港交易及結算所有限公司 公司名稱: 前海健康控股有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00911 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.4 | HKD | ...
港股公告精选|药明康德中期盈利同比增逾一倍 中国铁建上半年新签合同额超万亿
Xin Lang Cai Jing· 2025-07-28 12:51
Company News - China Railway Construction (01186.HK) reported a new contract amount of approximately 1,056.17 billion yuan for the first half of the year, a year-on-year decrease of 4.04% [2] - China Metallurgical Group (01618.HK) announced a new contract amount of 548.2 billion yuan for the first half of the year, down 19.1% year-on-year [2] - Sichuan Chengyu Expressway (00107.HK) won the bid for the G5 Jingkun Expressway Chengdu to Ya'an section expansion project, with a total investment of approximately 28.548 billion yuan [2] - Road King Infrastructure (01098.HK) reported total property sales of 5.232 billion yuan for the first half of the year, a decrease of 28.37% year-on-year [2] - Amax Holdings (00880.HK) plans to acquire a property in Hengqin for 724.2 million yuan to diversify its business portfolio [2] - Chaoyue Eye Hospital (02219.HK) signed a construction contract for the first phase of its comprehensive medical facility project, with a contract value of 223 million yuan [2] - Bay Area Development (00737.HK) reported total toll revenue of 243 million yuan for June, a year-on-year decrease of 4% [2] - Decent Pharmaceuticals-B (06996.HK) received approval for its drug, Hivio®, for the second-line treatment of multiple myeloma in China [2] - Tianchen Holdings (01201.HK) plans to invest 30 million yuan to establish a joint venture in Shenzhen for new energy heavy truck charging stations [2] Performance Summary - WuXi AppTec (02359.HK) reported mid-year revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit of 8.561 billion yuan, up 101.92% year-on-year [3] Earnings Announcements - China Nonferrous Mining (01258.HK) issued a profit warning, expecting mid-term net profit of approximately 258 million USD, a year-on-year increase of about 18% [4] - Hualing Pharmaceutical-B (02552.HK) issued a profit warning, expecting mid-term net profit of approximately 1.184 billion yuan, turning from loss to profit [4] - Little Yellow Duck (02250.HK) issued a profit warning, expecting mid-term revenue to increase by over 30% year-on-year [4] - Qingci Games (06633.HK) issued a profit warning, expecting mid-term net profit to increase by approximately 78%-130% year-on-year [4] - Goodbaby International (01086.HK) issued a profit warning, expecting mid-term net profit to decrease by approximately 40%-50% year-on-year [4] - Qianhai Health (00911.HK) issued a profit warning, expecting mid-term net profit to decrease by approximately 60%-70% year-on-year [4] - Tianan Health (00383.HK) issued a profit warning, expecting mid-term net profit to decrease to approximately 7 million to 17 million HKD [4] - Pacific Network (00543.HK) issued a profit warning, expecting mid-term net loss of approximately 5 million to 15 million yuan [4] Buyback and Increase Dynamics - HSBC Holdings (00005.HK) repurchased 348,700 shares for approximately 35.487 million HKD at a price of 101.4-102 HKD [3] - China Eastern Airlines (00670.HK) repurchased 2.5 million shares for approximately 7.4983 million HKD at a price of 2.97-3.03 HKD [3] - Founder Holdings (00418.HK) canceled a total of 17.9962 million shares that had been repurchased [3]
前海健康(00911) - 盈利警告
2025-07-28 08:54
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準 確性或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 Qianhai Health Holdings Limited 前海健康控股有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號:911) 盈利警告 本公告由前海健康控股有限公司(「本公司」,連同其附屬公司統稱「本集團」)董事(「 董 事」)會(「董事會」)根據香港聯合交易所有限公司證券上市規則(「上市規則」)第 13.09條及香港法例第571章證券及期貨條例第XIVA部項下之內幕消息條文(定義見上市 規則)作出。 董事會謹此知會本公司股東(「股東」)及潛在投資者,根據對本集團截至二零二五年六 月三十日止六個月(「本期間」)之未經審核綜合管理賬目(「管理賬目」)之初步評估 以及董事會目前可得信息,預計本期間本公司擁有人之溢利比二零二四年同期下降約60% 至70%。下降主要歸因於本期間因市場價格下跌,本集團以較低的銷售價格銷售電子元件 產品並承擔了較高的成本,導致毛利潤和毛利率的減少。 承董事會命 ...
前海健康(00911) - 於二零二五年六月二十五日举行之股东週年大会之表决结果
2025-06-25 10:37
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示概不就因本公告全部或任何部份內容所 產生或因依 賴該等內容而引起之任何損失承擔任何責任。 Qianhai Health Holdings Limited 前海健康控股有限公司 (於開曼群島註冊成立的有限公司) (股份代號: 911 ) 於二零二五年六月二十五日舉行之股東週年大會 之表決結果 投票表決結果如下: | | | 票數(%) | | 由股東 | | --- | --- | --- | --- | --- | | | 普通決議案 | 贊成 | 反對 | 通過 | | 1. | 省覽及批准本公司及其附屬公司截至 | 89,263,602 | 0 | 是 | | | 二零二四年十二月三十一日止年度之 | (100%) | (0%) | | | | 經審核綜合財務報表以及本公司董事 | | | | | | 會及本公司之獨立核數師的報告。 | | | | | 2. | (a) 重選湯裕源先生為董事。 | 89,263,602 | 0 | 是 | | | | (100%) | (0%) | | ...
前海健康(00911) - 董事会提名委员会职权范围
2025-06-25 10:10
QIANHAI HEALTH HOLDINGS LIMITED 前海健康控股有限公司 (the "Company" and "本公司") Terms of reference of the Nomination Committee (the "Committee") of the Board (the "Board") of Directors (the "Directors") of the Company 董事("董事")會("董事會") 提名委員會("委員會") 權責範圍及程序 (中文本爲翻譯稿,僅供參考用) QIANHAI HEALTH HOLDINGS LIMITED 前海健康控股有限公司 董事會提名委員會職權範圍 Terms of reference of the Nomination Committee of the Board of Directors 1. Constitution 組成 1.1 The Committee is established pursuant to a resolution passed by the Board at its meeting held on 9 ...
前海健康(00911) - 董事名单以及角色及职能
2025-06-25 10:08
Qianhai Health Holdings Limited 前海健康控股有限公司 ( 於開曼群島註冊成立的有限公司) (股份代號:911) 董事名單以及角色及職能 黃志群先生 (董事會主席) 陳凱犇先生 陳琦先生 湯裕源先生 源自立先生 獨立非執行董事 李煒先生 梁振東先生 吳鴻茹女士 董事會設立三個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 黃志群先生 | | - | - | - | | 陳凱犇先生 | | - | - | - | | 陳琦先生 | | - | - | - | | 湯裕源先生 | | - | - | - | | 源自立先生 | | - | 成員 | 成員 | | 李煒先生 | | 成員 | 主席 | 主席 | | 梁振東先生 | | 成員 | 成員 | 成員 | | 吳鴻茹女士 | | 主席 | - | 成員 | 香港,二零二五年六月二十五日 前海健康控股有限公司(「本公司」,連同其附屬公司,統稱「本集團」 ...
前海健康(00911) - 委任提名委员会成员
2025-06-25 10:05
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責, 對其準確性或完整 性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部分內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 香港,二零二五年六月二十五日 於本公告日期,非執行董事為黃志群先生、陳凱犇先生及陳琦先生;執行董事為湯裕源先生及 源自立先生及獨立非執行董事為李煒先生、梁振東先生及吳鴻茹女士。 1 前海健康控股有限公司(「本公司」)董事會(「董事會」)欣然宣布,本公司之獨立非執行 董事吳鴻茹女士已獲委任為本公司之提名委員會(「提名委員會」)之成員,自二零二五年六 月二十五日起生效。 於上述委任後,提名委員會由李煒先生(提名委員會主席)、源自立先生、梁振東先生及吳鴻 茹女士組成。 董事會謹藉此衷心歡迎吳鴻茹女士加入提名委員會。 承董事會命 前海健康控股有限公司 主席 黃志群 Qianhai Health Holdings Limited 前海健康控股有限公司 (於開曼群島註冊成立的有限公司) (股份代號: 911) 委任提名委員會成員 ...
前海健康(00911) - 股东週年大会通告
2025-05-26 08:31
香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不對因本通告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 前海健康控股有限公 司 Qianhai Health Holdings Limited (於開曼群島註冊成立的有限公司) (股份代號:911) 股東週年大會通告 茲通告前海健康控股有限公司(「本公司」)謹訂於二零二五年六月二十五日(星期三) 上午十一時三十分假座香港上環文咸東街35-45B號2樓室舉行股東週年大會,藉以 處理下列事項: 前海健康控股有限公司 主席 除非另有說明,否則本通告中所用詞彙與本公司日期為二零二五年五月二十七日致 股東之通函(「通函」)所界定者具有相同涵義。 普通決議案 1 1. 省覽及批准本公司及其附屬公司截至二零二四年十二月三十一日止年度之經 審核綜合財務報表以及董事會報告及本公司之核數師報告; 2. 考慮及酌情批准下列各項決議案(各自作為獨立之決議案): (a) 重選湯裕源先生為董事; (b) 重選源自立先生為董事; (c) 重選陳凱犇先生為董事; (d) 重選吳鴻茹女士為董事 ...
前海健康(00911) - 重选退任董事及股东週年大会通告
2025-05-26 08:29
此乃要件 請即處理 閣下如對本通函任何方面有疑問,應諮詢 閣下之股票經紀或其他註冊證券商、銀行經理、 律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下之所有前海健康控股有限公司股份,應立即將本通函及隨附之代 表委任表格交予買主或承讓人,或送交經手買賣或轉讓之銀行、股票經紀或其他代理商,以 便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責,對其準 確性或完整性亦不發表任何聲明,並明確表示概不就因本通函全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本通函所用詞彙應與本通函「釋義」一節所界定者具相同涵義。 前海健康控股有限公 司 Qianhai Health Holdings Limited (於開曼群島註冊成立的有限公司) (股份代號:911) 重選退任董事 及 股東週年大會通告 前海健康控股有限公司謹訂於二零二五年六月二十五日(星期三)上午十一時三十分假座香 港上環文咸東街35-45B號2樓舉行股東週年大會,召開大會之通告載於本通函第10至12頁。 隨函亦附奉股東週年大會適用之代表委任表格。無論 閣下能否出席該大會,謹請按照代表 委 ...
前海健康(00911) - 2024 - 年度财报
2025-04-28 08:35
Financial Performance - The company reported revenue of approximately HKD 519.7 million for the fiscal year 2024, a decrease from HKD 961.3 million in 2023, primarily due to a decline in sales volume [6]. - The gross profit for the year was HKD 29.7 million, compared to a gross loss of HKD 35.6 million in the previous year, resulting in a gross margin of 5.7% [9]. - The company achieved a profit attributable to owners of approximately HKD 1.3 million, a significant turnaround from a loss of HKD 52.7 million in the prior year [12]. - Total assets decreased to HKD 407.3 million from HKD 478.1 million, while total liabilities significantly reduced to HKD 21.7 million from HKD 94.0 million [6]. - The company anticipates continued volatility in ICs and NAND flash wafer prices, impacting future revenue stability [8]. - Other losses included an additional provision of approximately HKD 60.4 million for loss contracts due to unexpected costs exceeding anticipated economic benefits [11]. - The company maintained a net asset value of HKD 385.6 million, slightly up from HKD 384.1 million in the previous year [6]. - The group anticipates growth opportunities in the electronic components industry driven by advanced technologies such as third-generation semiconductor materials, 5G, AI, and automotive electronics [13]. Asset and Liability Management - As of December 31, 2024, the current ratio is approximately 18.1 times, significantly up from 4.8 times in 2023 [14]. - Total assets as of December 31, 2024, are approximately HKD 407.3 million, down from HKD 478.1 million in 2023 [14]. - The group’s capital debt ratio is approximately 5.3% as of December 31, 2024, compared to 19.7% in 2023 [14]. - Inventory held as of December 31, 2024, is approximately HKD 188.8 million, a decrease from HKD 329.8 million in 2023 [15]. - Prepayments for inventory purchases amount to approximately HKD 70.6 million as of December 31, 2024, down from HKD 102.0 million in 2023 [16]. - Trade receivables as of December 31, 2024, are approximately HKD 98.7 million, with an expected credit loss provision of about HKD 0.3 million [18]. - Cash and cash equivalents are approximately HKD 23.3 million as of December 31, 2024, an increase from HKD 19.5 million in 2023 [19]. - The group has no borrowings as of December 31, 2024 [20]. Corporate Governance - The company has established a robust internal control system to ensure compliance and accountability, adhering to the corporate governance code as per the listing rules [40]. - The board consists of eight members, including three non-executive directors, two executive directors, and three independent non-executive directors, ensuring a balanced power structure [43]. - The company emphasizes a diverse board composition, considering various factors such as gender, age, ethnicity, and professional experience, to enhance governance effectiveness [48]. - The company has implemented an anti-corruption policy and reporting mechanism to promote ethical behavior and compliance among employees [41]. - The board has mechanisms in place to ensure independent viewpoints are considered, including encouraging active participation from independent non-executive directors [47]. - The company is currently seeking a suitable candidate for the CEO position, which has been vacant since July 18, 2019 [46]. - The company has adopted a code of conduct for securities trading by directors, ensuring compliance with the standards set forth in the listing rules [42]. - The board conducts annual reviews of its diversity policy and its effectiveness in achieving measurable goals [48]. Employee Relations and Compensation - The total salary and related costs for the 16 employees as of December 31, 2024, amount to approximately HKD 6.6 million [30]. - The company has established an annual review system to assess employee performance, which forms the basis for salary increases, bonuses, and promotions [30]. - The board believes in maintaining a good relationship with employees [30]. - The company has adopted a share option scheme to reward directors and eligible employees based on individual performance [30]. - The company has maintained a zero-tolerance policy towards any form of discrimination and has not reported any incidents of workplace discrimination or harassment this year [190]. - The company offers competitive and fair compensation and benefits to attract high-quality talent, with regular salary reviews to recognize employee contributions [190]. Risk Management - The company has established a risk management and internal control system to minimize procurement price risks and protect assets [80]. - The board believes the risk management and internal control systems are adequate and effective as of December 31, 2024 [82]. - The main risks faced by the company include credit risk, currency risk, and liquidity risk [160]. Environmental, Social, and Governance (ESG) Initiatives - The company is committed to environmental responsibility by managing its operational impact and improving resource efficiency [153]. - The company has established an Environmental, Social, and Governance (ESG) working group to assess and manage ESG-related risks [166]. - The ESG report emphasizes the importance of stakeholder engagement and has conducted a materiality assessment to identify key concerns [167][171]. - The company has implemented an environmental strategy focused on "saving, reusing, and recycling" to enhance energy efficiency and reduce carbon emissions [179]. - The company has established a collection area for recyclable materials, including paper, plastic, and metal, to support waste recycling efforts [175]. - The company is committed to complying with all relevant environmental laws and regulations applicable to its operations [172]. - The company has not recorded any significant non-compliance issues with applicable environmental protection laws and regulations as of December 31, 2024 [186]. Shareholder Relations - The board is committed to effective communication with shareholders to enhance investor relations and ensure timely disclosure of information [88]. - Shareholders holding at least 10% of the paid-up capital can request the board to convene a special general meeting [89]. - The company has updated its articles of association to comply with the latest regulatory requirements regarding paperless listing systems [93]. - The company reported total distributable reserves of approximately HKD 262,991,000 as of December 31, 2024, compared to HKD 233,372,000 in 2023, reflecting an increase of about 12.5% [107]. Compliance and Legal Matters - The company has adhered to relevant laws and regulations that significantly impact its business operations [151]. - The company has implemented appropriate internal controls and quality control measures to ensure compliance with the Sale of Goods Ordinance [156]. - The group complies with all applicable laws and regulations related to product responsibility, with no known violations during the year [199]. - The group has adopted high-standard security and confidentiality measures to protect stakeholders' personal data [200].